Last reviewed · How we verify
MVA-BN vaccine
MVA-BN is a live attenuated vaccinia virus vaccine that stimulates immune responses against monkeypox virus antigens to provide protection against mpox infection.
MVA-BN is a live attenuated vaccinia virus vaccine that stimulates immune responses against monkeypox virus antigens. Used for Monkeypox (mpox) prevention in adults at risk, Post-exposure prophylaxis for monkeypox.
At a glance
| Generic name | MVA-BN vaccine |
|---|---|
| Also known as | JYNNEOS |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Live attenuated viral vaccine |
| Target | Monkeypox virus antigens (vaccinia virus-vectored) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
MVA-BN (modified vaccinia Ankara-Bavarian Nordic) is a replication-competent orthopoxvirus vaccine derived from vaccinia virus. It expresses immunogenic proteins from monkeypox virus, triggering both cellular and humoral immune responses. The vaccine primes T-cell and B-cell immunity to provide protection against mpox infection and disease.
Approved indications
- Prevention of mpox (monkeypox) infection in adults at risk of exposure
- Post-exposure prophylaxis for mpox
Common side effects
- Injection site reactions (erythema, swelling, pain)
- Myalgia
- Fatigue
- Headache
- Fever
- Nausea
Key clinical trials
- A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox (PHASE2)
- Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC (PHASE4)
- A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers (PHASE1)
- Phase 3 Maternal Safety & Immunogenicity Trial of MVA-BN® in DRC (PHASE3)
- Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults (PHASE1, PHASE2)
- Evaluate the Safety and Immunogenicity of the MVA-SIBP Vaccine in the Democratic Republic of the Congo (PHASE2)
- Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections (PHASE2)
- Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MVA-BN vaccine CI brief — competitive landscape report
- MVA-BN vaccine updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI